Herceptin Biosimilar Market Accelerates 23.2% CAGR Forecast (2022-2030)

The global Herceptin biosimilar market has demonstrated significant growth in recent years, and this trend is expected to continue over the forecast period. Valued at USD 1,795 million in 2021, the market is projected to reach USD 11,287 million by 2030, reflecting a compound annual growth rate (CAGR) of 23.2% from 2022 to 2030. This robust growth is driven by several factors, including the rising prevalence of gastric and breast cancer, a strong product pipeline from leading pharmaceutical companies, and advancements in the healthcare sector.

REQUEST A $1000 DISCOUNT ON CREDIT CARD PURCHASE: https://www.acumenresearchandconsulting.com/inquiry-before-buying/886

Market Drivers

1. Rising Prevalence and Incidence of Gastric and Breast Cancer

o The increasing prevalence of gastric and breast cancer is a major driver for the Herceptin biosimilar market. Breast cancer, in particular, is one of the most common cancers among women worldwide, with millions of new cases diagnosed each year. The need for effective treatment options is crucial, and Herceptin biosimilars offer a cost-effective alternative to the original Herceptin (trastuzumab) therapy.

o The World Health Organization (WHO) reports that breast cancer alone accounts for approximately 15% of all cancer deaths among women. With the global incidence of cancer on the rise, the demand for biosimilar drugs that can provide similar therapeutic benefits at a lower cost is expected to grow significantly.

Download Sample Report Copy of This Report from Here: https://www.acumenresearchandconsulting.com/request-sample/886

2. Strong Product Pipeline from Leading Companies

o Major pharmaceutical companies are investing heavily in the development of Herceptin biosimilars. Companies such as Mylan, Teva Pharmaceuticals, and Pfizer have already launched or are in the process of developing biosimilars for Herceptin. These companies are leveraging their extensive research and development capabilities to bring high-quality biosimilars to the market.

o The competitive landscape is further intensified by collaborations and partnerships between biotechnology firms and large pharmaceutical companies, which are aimed at accelerating the development and commercialization of these biosimilars. This strong product pipeline is expected to drive market growth over the forecast period.

3. Increasing Advancement in the Healthcare Sector

o The healthcare sector is witnessing rapid advancements in biotechnology and pharmaceutical research, leading to the development of innovative treatment options. The introduction of biosimilars is a testament to these advancements, as they offer comparable efficacy and safety profiles to original biologic drugs but at a reduced cost.

o Technological advancements in drug development and manufacturing processes have improved the quality and availability of biosimilars. These improvements are facilitating faster regulatory approvals and market entry, thereby driving the growth of the Herceptin biosimilar market.

4. Endorsement of Innovative Herceptin Biosimilar Prescription Meds by Key Companies

o Leading pharmaceutical companies are endorsing innovative Herceptin biosimilar medications, which is helping to build trust and acceptance among healthcare professionals and patients. These endorsements are often supported by extensive clinical trial data that demonstrate the safety and efficacy of biosimilars.

o The positive perception and acceptance of Herceptin biosimilars by the medical community are crucial for market growth, as they influence prescribing patterns and patient adoption rates.

Market Restraints

1. Existence of Alternatives

o While Herceptin biosimilars offer a cost-effective alternative to the original drug, the market also faces competition from other treatment options. Alternative therapies, including other monoclonal antibodies and small molecule drugs, are available for the treatment of gastric and breast cancer. These alternatives can limit the uptake of Herceptin biosimilars in some patient populations.

o Additionally, the development of new targeted therapies and personalized medicine approaches may pose a challenge to the growth of the Herceptin biosimilar market.

Herceptin Biosimilar Market Segmentation

The global herceptin biosimilar market segmentation based on the application, end-user and geographical region.

Market by Application
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lymphoma
• Others

Market by End-User
• Hospital & Clinics
• Oncology Centers
• Others

2. High Costs for Development

o The development of biosimilars is a complex and costly process, requiring significant investment in research and development, clinical trials, and regulatory compliance. These high development costs can be a barrier for smaller companies and new entrants to the market.

o Moreover, the need for rigorous clinical trials to demonstrate biosimilarity and the subsequent regulatory approvals add to the overall cost and time required to bring a biosimilar to market.

3. Significant Side Effects Associated with Herceptin

o Herceptin, like other monoclonal antibody therapies, is associated with certain side effects, including cardiotoxicity, infusion reactions, and pulmonary toxicity. These side effects can limit the use of Herceptin biosimilars, particularly in patients with pre-existing conditions or those who are at higher risk of adverse reactions.

o The management of these side effects requires careful monitoring and may necessitate additional medical interventions, which can increase the overall cost of treatment and impact patient adherence to therapy.

Herceptin Biosimilar Market Players

Currently limited numbers of companies are present in the market. Herceptin was developed by Roche and is still holding the patient in some of the countries. However, the companies like Pfizer, TEVA and others are continuously trying to develop the new generic drugs so as to enter in the market. With the expiry of the patent for the drug in 2019, the herceptin biosimilar market will possess a huge growth. Some of the prominent global herceptin biosimilar market companies are Amgen Inc., Biocon Limited, Merck & Co., Inc., Gedeon Richter Plc, Mabion SA, Roche Holding AG, AryoGen Biopharma, Pfizer Inc., Accord Healthcare Ltd, Genor Biopharma Company Ltd, Mylan N.V, and Samsungbioepis Co., Ltd.

Market Opportunities

1. Strategic Acquisitions and Mergers by Major Influencers

o Strategic acquisitions and mergers among major pharmaceutical companies present significant growth opportunities for the Herceptin biosimilar market. These strategic moves can enhance the capabilities of companies in terms of research and development, manufacturing, and distribution, enabling them to bring biosimilars to market more efficiently.

o Collaborations and partnerships also allow companies to share resources and expertise, reducing the financial burden and risk associated with biosimilar development. These strategic alliances can accelerate the commercialization of Herceptin biosimilars and expand their reach in the global market.

2. Increase in Healthcare Spending

o The global increase in healthcare spending, particularly in emerging economies, is expected to drive the demand for Herceptin biosimilars. Governments and healthcare organizations are investing more in healthcare infrastructure, access to medicines, and innovative treatment options to improve patient outcomes.

o As healthcare budgets increase, there is a growing emphasis on cost-effective treatment options. Herceptin biosimilars, with their potential to reduce treatment costs while maintaining therapeutic efficacy, are well-positioned to benefit from this trend.

3. Rising Demand in Emerging Markets

o Emerging markets, particularly in Asia-Pacific and Latin America, present lucrative opportunities for the Herceptin biosimilar market. These regions have a high prevalence of gastric and breast cancer, and the demand for affordable treatment options is increasing.

o The improving healthcare infrastructure, rising awareness about cancer treatment, and supportive government policies in these regions are expected to drive the adoption of Herceptin biosimilars. Companies that can effectively navigate the regulatory landscape and establish strong distribution networks in these markets are likely to gain a competitive edge.

Herceptin Biosimilar Market Table of Content:

CHAPTER 1. Industry Overview of Herceptin Biosimilar Market
CHAPTER 2. Research Approach
CHAPTER 3. Market Dynamics And Competition Analysis
CHAPTER 4. Herceptin Biosimilar Market Revenue By Application
CHAPTER 5. Herceptin Biosimilar Market Revenue By End-User
CHAPTER 6. North America Herceptin Biosimilar Market By Country
CHAPTER 7. Europe Herceptin Biosimilar Market By Country
CHAPTER 8. Asia-Pacific Herceptin Biosimilar Market By Country
CHAPTER 9. Latin America Herceptin Biosimilar Market By Country
CHAPTER 10. Middle East & Africa Herceptin Biosimilar Market By Country
CHAPTER 11. Player Analysis Of Herceptin Biosimilar Market
CHAPTER 12. Company Profile

Conclusion

The global Herceptin biosimilar market is poised for substantial growth over the forecast period, driven by factors such as the rising prevalence of gastric and breast cancer, strong product pipelines, advancements in healthcare, and endorsements from key companies. While the market faces challenges from alternative therapies, high development costs, and side effects, strategic acquisitions, increased healthcare spending, and opportunities in emerging markets present significant growth prospects. Companies that can effectively address these challenges and capitalize on the opportunities are expected to thrive in the competitive landscape of the Herceptin biosimilar market.

Ask Query Here: Richard@acumenresearchandconsulting.com or sales@acumenresearchandconsulting.com

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/886

Browse for more Related Reports
https://www.globenewswire.com/news-release/2022/08/22/2502270/0/en/Herceptin-Biosimilar-Market-Size-is-expected-to-be-worth-USD-11-287-Million-by-2030-at-a-CAGR-of-23-2-Owing-to-Rising-Prevalence-and-Incidence-of-Gastric-and-Breast-Cancer.html

201, Vaidehi-Saaket, Baner - Pashan Link Rd, Pashan, Pune, Maharashtra 411021

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

This release was published on openPR.